Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 11
Submit an article Journal homepage
94
Views
15
CrossRef citations to date
0
Altmetric
Review

How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis

Camille Locht INSERM U629, Lille, France; Institut Pasteur de Lille, 1, rue du Prof. Calmette, F-59019 Lille Cedex, France +33 3 20 87 11 51; +33 3 20 87 11; [email protected]
, PhD,
Carine Rouanet INSERM U629, Lille, France; Institut Pasteur de Lille, 1, rue du Prof. Calmette, F-59019 Lille Cedex, France +33 3 20 87 11 51; +33 3 20 87 11; [email protected]
, PhD,
Jean-Michel Hougardy Université Libre de Bruxelles (U.L.B.), Laboratory of Vaccinology and Mucosal Immunity, Belgium
, MD &
FranÇoise Mascart Université Libre de Bruxelles (U.L.B.), Laboratory of Vaccinology and Mucosal Immunity, Belgium; Hôpital Erasme, Immunobiology Clinic, Brussels, Belgium
, MD PhD
Pages 1665-1677 | Published online: 26 Oct 2007

Bibliography

  • WORLD HEALTH ORGANIZATION: TB deaths reach historic levels. WHO Press, 21 March (1996):1-3.
  • WORLD HEALTH ORGANIZATION: WHO Report (1994) WHO/TB/94.177.
  • WORLD HEALTH ORGANIZATION: Global tuberculosis control: surveillance, planning, financing. WHO Report. Geneva, Switzerland (2007) WHO/HTM/TB/2007.376.
  • DYE C, WATT CJ, BLEED DM, HOSSEINI SM, RAVIGLIONE MC: Evolution of tuberculosis control and prospects for tuberculosis incidence, prevalence, and death globally. JAMA (2005) 293:2767-2775.
  • DYE C, SCHEEL S, DOLIN R, PATHANIA G, RAVIGLIONE MC: Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA (1999) 182:677-686.
  • HOLMES CB, LOSINA E, WALENSKY RP, YAZDANPANAH Y, FREEBERG KA: Review on human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan countries. Clin. Infect. Dis. (2003) 36:652-662.
  • SELWYN PA, HARTEL D, LEWIS VA et al.: A prospective study on the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. (1989) 320:545-550.
  • STEINGART KR, NG V, HENRY M et al.: Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis. A systematic review. Lancet Infect. Dis. (2006) 6:664-674.
  • URBANCZIK R: Present position of microscopy and of culture in diagnostic mycobacteriology. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] (1985) 260:81-87.
  • SBARBARO JA: Skin testing in the diagnosis of tuberculosis. Semin. Respir. Infect. (1986) 1:234-248.
  • MENZIES D: Interpretation of repeated tuberculin tests: boosting, conversion and reversion. Am. J. Respir. Crit. Care Med. (1999) 159:15-21.
  • PAI M, DHEDA K, CUNNINGHAM J, SCANO F, O'BRIEN R: T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect. Dis. (2007) 7:428-438.
  • KHATRI GR, FRIEDEN TR: Controlling tuberculosis in India. N. Engl. J. Med. (2002) 347:1420-1425.
  • RAVIGLIONE MC, PIO A: Evolution of WHO policies for tuberculosis control, 1948 – 2001. Lancet (2002) 350:624-629.
  • ZIGNOL M, HOSSEINI MS, WRIGHT A et al.: Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. (2006) 194:479-485.
  • ISEMAN MD: Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. (1993) 329:784-791.
  • SHAH NS, WRIGHT A, BAI GH et al.: Worldwide emergence of extensively drug-resistant tuberculosis. Em. Infect. Dis. (2007) 13:380-387.
  • FINE PE: Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 346:1339-1345.
  • MARTIN C: Tuberculosis vaccines: past, present and future. Curr. Opin. Pulm. Med. (2006) 12:186-191.
  • RODRIGUES LC, DIWAN VK, WHEELER LG: Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. (1993) 22:1154-1158.
  • TRUNZ B, FINE P, DYE C: Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet (2006) 367:1173-1180.
  • COLDITZ GA, BREWER TF, BERKEY CS et al.: Efficacy of BCG vaccine in the prevention of tuberculosis – meta-analysis of the published literature. JAMA (1994) 271:698-702.
  • BROSCH R, GORDON SV, GARNIER T et al.: Genome plasticity of BCG and the impact on vaccine efficacy. Proc. Natl. Acad. Sci. USA (2007) 104:5596-5601.
  • RODRIGUES LC, PEREIRA SM, CUNHA SS et al.: Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil; the BCG-REVAC cluster-randomised trial. Lancet (2005) 366:1290-1295.
  • WELLS WF, RADCLIFFE HL, CRUMB C: On the mechanism of droplet nuclei infection. Am. J. Hyg. (1948) 47:11-28.
  • RUSSELL DG: Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. (2001) 2:569-577.
  • RUSSELL DG: Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. (2007) 5:39-47.
  • MEDLAR EM: The pathogenesis of minimal pulmonary tuberculosis: a study of 1225 necropsies in cases of sudden and unexpected death. Am. Rev. Tuberc. (1948) 58:583-611.
  • SWEANY HC, COOK CE, KEGERREIS RA: A study of the position of primary cavities in pulmonary tuberculosis. Am. Rev. Tuberc. (1931) 24:558-582.
  • LINCOLN EM, GILBERT LA, MORALES SM: Chronic pulmonary tuberculosis in individuals with known previous primary tuberculosis. Dis. Chest (1960) 38:473-482.
  • STEAD WW: The pathogenesis of pulmonary tuberculosis among older persons. Am. Rev. Respir. Dis. (1965) 91:811-822.
  • NEYROLLES O, HERNANDEZ-PANDO R, PIETRI-ROUXEL F et al.: Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS One (2006) 1:E43.
  • COMSTOCK GW: The epidemiology of tuberculosis. Am. Rev. Respir. Dis. (1982) 125(Suppl.):8-16.
  • AMERICAN THORACIC SOCIETY AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. (2000) 161:S221-S247.
  • GRZYBOWSKI S, ALLEN EA: The challenge of tuberculosis in decline. A study based on the epidemiology of tuberculosis in Ontario, Canada. Am. Rev. Respir. Dis. (1964) 90:707-720.
  • STEAD NV, LOFGREN JP: Does the risk of tuberculosis increase with old age? J. Infect. Dis. (1983) 147:951-955.
  • DANNENBERG AM Jr, ROOK GAW: Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage-activating immune responses – dual mechanisms that control bacillary multiplication. In: Tuberculosis, Pathogenesis, Protection, and Control. Bloom BR (Ed.), ASM Press, Washington DC, USA (1994):459-483.
  • CANETTI G: Present aspects of bacterial resistance in tuberculosis. Am. Rev. Respir. Dis. (1965) 92:687-703.
  • KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a TNF-a-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
  • LAZAREVIC V, FLYNN JL: CD8+ T cells in tuberculosis. Am. J. Respir. Crit. Care Med. (2002) 166:1116-1121.
  • VAN PINXTEREN LA, CASSIDY JP, SMEDEGAARD BH, AGGER EM, ANDERSEN P: Control of latent Mycobacterium tuberculosis infection is dependent on CD8+ T cells. Eur. J. Immunol. (2000) 30:3689-3698.
  • MITTRUCKER HW, STEINHOFF U, KOHLER A et al.: Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc. Natl. Acad. Sci. USA (2007) 104:12434-12439.
  • MCMURRAY DN: Guinea pig model of tuberculosis. In: Tuberculosis, Pathogenesis, Protection, and Control. Bloom BR (Ed.), ASM Press, Washington DC, USA (1994):135-147.
  • REES RJW, HART D'A: Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br. J. Exp. Pathol. (1961) 42:83-88.
  • MCCUNE RM, TOMPSETT R: Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in tissues despite prolonged antimicrobial therapy. J. Exp. Med. (1956) 104:737-762.
  • MCCUNE RM, MCDERMOTT W, TOMPSETT R: The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by administration of pyrazinamide and a companion drug. J. Exp. Med. (1956) 104:763-802.
  • WAYNE LG, SRAMEK HA: Metronidazol is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1994) 38:2054-2058.
  • FLYNN JL: Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect. (2006) 8:1179-1188.
  • WAYNE LG: Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13:908-914.
  • CARDONA PJ, RUIZ-MANZANO J: On the nature of Mycobacterium tuberculosis-latent bacilli. Eur. Respir. J. (2004) 24:1044-1051.
  • WAYNE LG, SOHASKEY CD: Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. (2001) 55:139-163.
  • SHERMAN DR, VOSKUIL M, SCHNAPPINGER D, LIAO R, HARRELL MI, SCHOOLNIK GK: Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding a-crystallin. Proc. Natl. Acad. Sci. USA (2001) 98:7534-7539.
  • RAJA A, UMA DEVI KR, RAMALINGAM B, BRENNAN PJ: Immunoglobulin G, A, and M responses in serum and circulating immune complexes elicited by the 16-kilodalton antigen of Mycobacterium tuberculosis. Clin. Diagn. Lab. Immunol. (2002) 9:308-312.
  • WILKINSON RJ, WILKINSON KA, DE SMET KA et al.: Human T- and B-cell reactivity to the 16 kDa a-crystallin protein of Mycobacterium tuberculosis. Scand. J. Immunol. (1998) 48:403-409.
  • VOSKUIL MI, SCHNAPPINGER D, VISCONTI KC et al.: Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. (2003) 198:705-713.
  • LEYTEN EM, LIN MY, FRANKEN KL et al.: Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. (2006) 8:2052-2060.
  • DEJERINE J: Recherche du bacille de Koch dans la tuberculose calcifiée. Compt. Rend. Soc. Biol. (1884) 36:500-505.
  • OPIE EL, ARONSON JD: Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculous lesions. Arch. Pathol. Lab. Med. (1927) 4:1-21.
  • FELDMAN WH, BAGGENSTOSS AH: The residual infectivity of the primary complex of tuberculosis. Am. J. Pathol. (1938) 14:473-493.
  • MEDLAR EM, BERNSTEIN S, STEWARD DM: A bacteriologic study of resected tuberculous lesions. Am. Rev. Tuberc. (1952) 66:36-43.
  • HERNANDEZ-PANDO R, JEYANATHAN M, MENGISTU G et al.: Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet (2000) 356:2133-2137.
  • SHEPARD CC: Growth characteristics of tubercule bacilli and certain other mycobacteria in HeLa cells. J. Exp. Med. (1957) 105:39-48.
  • BERMUDEZ LE, GOODMAN J: Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect. Immun. (1996) 64:1400-1406.
  • MCDONOUGH KA, KRESS Y: Cytotoxicity of lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect. Immun. (1995) 63:4802-4811.
  • METHA PK, KING CH, WHITE EH, MURTAGH JJJR, QUINN FD: Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication. Infect. Immun. (1996) 64:2673-2679.
  • BERMUDEZ LE, SANGARI FJ, KOLONOSKI P, PETROFSKY M, GOODMAN J: The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model for the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells. Infect. Immun. (2002) 70:140-146.
  • MENOZZI FD, ROUSE JH, ALAVI M et al.: Identification of a heparin-binding hemagglutinin present in mycobacteria. J. Exp. Med. (1996) 184:993-1001.
  • PETHE K, ALONSO S, BIET F et al.: The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature (2001) 412:190-194.
  • LOCHT C, RAZE D, ROUANET C, GENISSET C, SEGERS J, MASCART F: The mycobacterial heparin-binding hemagglutinin, virulence factor and antigen useful for diagnostics and vaccine development. In: The Mycobacterial Cell Wall. DaffÉ M, Reyrat JM (Eds), ASM Press, Washington DC, USA (2007) (In Press).
  • MENOZZI FD, BISCHOFF R, FORT E, BRENNAN MJ, LOCHT C: Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Proc. Natl. Acad. Sci. USA (1998) 95:12625-12630.
  • DELOGU G, BRENNAN MJ: Functional domains present in the mycobacterial hemagglutinin HBHA. J. Bacteriol. (1999) 181:7464-7469.
  • PETHE K, AUMERCIER M, FORT E, GATOT C, LOCHT C, MENOZZI FD: Characterization of the heparin-binding site of the mycobacterial heparin-binding hemagglutinin adhesin. J. Biol. Chem. (2000) 275:14273-14280.
  • DUPRES V, MENOZZI FD, LOCHT C et al.: Nanoscale mapping and functional analysis of individual adhesions on living bacteria. Nat. Methods (2005) 2:515-520.
  • PETHE K, BIFANI P, DROBECQ H et al.: Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc. Natl. Acad. Sci. USA (2002) 99:10759-10764.
  • HOST H, DROBECQ H, LOCHT C, MENOZZI FD: Enzymatic methylation of the Mycobacterium tuberculosis heparin-binding haemagglutinin. FEMS Microbiol. Lett. (2007) 268:144-150.
  • MUELLER-ORITZ SL, SEPULVEDA E, OLSEN MR, JAGANNATH C, WANGER AR, NORRIS SJ: Decreased infectivity despite unaltered C3 binding by a ΔhbhA mutant of Mycobacterium tuberculosis. Infect. Immun. (2002) 70:6751-6760.
  • CHACKERIAN AA, ALT JM, PERERA TV, DASCHER CC, BEHAR SM: Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect. Immun. (2002) 70:4501-4509.
  • MENOZZI FD, REDDY VM, CAYET D et al.: Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. Microbes Infect. (2006) 8:1-9.
  • BALASUBRAMANIAN V, WIEGESHAUS EH, TAYLOR T, SMITH DW: Pathogenesis of tuberculosis: pathway to apical localization. Tuber. Lung Dis. (1994) 75:168-178.
  • DELOGU G, SANGUINETTI M, POSTERARO B, ROCCA S, ZANETTI S, FADDA G: The hbhA gene of Mycobacterium tuberculosis is specifically upregulated in the lungs but not in the spleens of aerogenically infected mice. Infect. Immun. (2006) 74:3006-3011.
  • CUNNINGHAM AC, MILNE DS, WILKES J, DARK JH, TETLEY TD, KIRBY JA: Constitutive expression of MHC and adhesion molecules by alveolar epithelial cells (type II pneumocytes) isolated from human lung and comparison with immunocytochemical findings. J. Cell Sci. (1994) 107:443-449.
  • DEBBABI H, GHOSH S, KAMATH AB et al.: Primary type II alveolar epithelial cells present microbial antigens to antigen-specific CD4+ T cells. Am. J. Physiol. Lung. Mol. Physiol. (2005) 289:L274-L279.
  • MASUNGI C, TEMMERMAN S, VAN VOOREN JP et al.: Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J. Infect. Dis. (2002) 185:513-520.
  • TEMMERMAN S, PETHE K, PARRA M et al.: Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat. Med. (2004) 10:935-941.
  • HOUGARDY JM, SCHEPERS K, PLACE S et al.: Heparin-binding hemagglutinin-induced IFN-γ release as a diagnostic tool for latent tuberculosis. PLoS One (2007):(In Press).
  • HORSBURGH CR: Priorities for the treatment of latent tuberculosis infection in the United States. N. Engl. J. Med. (2004) 350:2060-2067.
  • JASMER RM, NAHID P, HOPEWELL PC: Clinical practice: latent tuberculosis infection. N. Engl. J. Med. (2002) 347:1860-1866.
  • RICHELDI L: An update on the diagnosis of tuberculosis infection. Am. J. Respir. Crit. Care Med. (2006) 174:736-742.
  • FERRARA G, LOSI M, D'AMICO R et al.: Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet (2006) 367:1328-1334.
  • KANG YA, LE HW, YOON HI et al.: Discrepancy between the tuberculin skin test and the whole-blood interferon g assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA (2005) 293:2756-2761.
  • PHADKE MA, KSHIRSAGAR NA: Blood tests for diagnosis of tuberculosis. Lancet (2006) 368:282-283.
  • HOUGARDY JM, PLACE S, HILDEBRAND M et al.: Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am. J. Respir. Crit. Care Med. (2007) 176:409-416.
  • HOUGARDY JM, VERSCHEURE V, LOCHT C, MASCART F: In vitro expansion of CD4+CD25highFOXP3+CD127low/- regulatory T cells from peripheral blood lymphocytes of healthy Mycobacterium tuberculosis-infected humans. Microbes Infect. (2007) (In Press).
  • FLORES L, NAF S, HERNAEZ R, CONGET I, GOMIS R, ESMATJES E: Transforming growth factor-β at clinical onset of Type 1 diabetes mellitus. A pilot study. Diabet. Med. (2004) 21:818-822.
  • JAGIRDAR J, BEGIN R, DUFRESNE A, GOSWAMI S, LEE TC, ROM WN: Transforming growth factor-β (TGF-β) in silicosis. Am. J. Respir. Crit. Care Med. (1996) 154:1076-1081.
  • YAMAMOTO T, NOBLE NA, COHEN AH et al.: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int. (1996) 49:461-469.
  • TEMMERMAN ST, PLACE S, DEBRIE AS, LOCHT C, MASCART F: Effector functions of heparin-binding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis. J. Infect. Dis. (2005) 192:226-232.
  • LOCHT C, HOUGARDY JM, ROUANET C, PLACE S, MASCART F: Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (2006) 86:303-309.
  • PARRA M, PICKETT T, DELOGU G et al.: The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect. Immun. (2004) 72:6799-6805.
  • LI Z, HOWARD A, KELLEY C, DELOGU G, COLLINS F, MORRIS S: Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect. Immun. (1999) 67:4780-4786.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.